David R. Ha, PharmD, BCIDP

home / authors / david-r-ha-pharmd

Ha is an infectious diseases and antimicrobial stewardship pharmacist and program manager of antimicrobial stewardship in the Department of Quality at Stanford Health Care and lecturer in the Division of Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine in California.

Articles

Expanding the Antibiotic Stewardship Team Can Lead to Greater Adoption of Practices

Expanding the Antibiotic Stewardship Team Can Lead to Greater Adoption of Practices

Sean Van Helden, PharmD;David R. Ha, PharmD, BCIDP
March 27th 2024

There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.

Read More

Combination Antifungal for Invasive Mucormycosis: Yay or Nay?

Combination Antifungal for Invasive Mucormycosis: Yay or Nay?

Brian Lu, PharmD;David R. Ha, PharmD, BCIDP;William Alegria, PharmD, BCIDP
November 2nd 2022

There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.

Read More

Site Logo

Actively Involving Nurses in Antibiotic Stewardship

David R. Ha, PharmD, BCIDP;MARY BETTE FORTE, MSN-ED, RN
April 23rd 2018

Staff nurses are underused but potentially valuable contributors to antibiotic stewardship.

Read More

Latest Updated Articles

The Evolution of Lenacapavir in HIV Treatment
Published: July 24th 2024 | Updated: July 25th 2024
The Evolution of Lenacapavir in HIV Treatment
Contagion Summer 2024 Digital Edition
Published: July 22nd 2024 | Updated: July 27th 2024
Contagion Summer 2024 Digital Edition
Dovato Shown to be as Effective as Biktarvy for HIV Maintenance Therapy
Published: July 23rd 2024 | Updated: July 27th 2024
Dovato Shown to be as Effective as Biktarvy for HIV Maintenance Therapy
Efficacy of the Antibiotic Omadacycline in Treating Pneumonia
Published: July 22nd 2024 | Updated: July 22nd 2024
Efficacy of the Antibiotic Omadacycline in Treating Pneumonia
High Rates of HCV Reinfection in NYC
Published: July 23rd 2024 | Updated: July 27th 2024
High Rates of HCV Reinfection in NYC
FDA and European Commission Approve Therapy for Multidrug Resistant Tuberculosis
Published: July 3rd 2024 | Updated: July 27th 2024
FDA and European Commission Approve Therapy for Multidrug Resistant Tuberculosis
© 2024 MJH Life Sciences

All rights reserved.